Division of Neurology

Michael F. Mazurek

MD, FRCP(C)
 

Professor, Division of Neurology, Department of Medicine

 

 

Research Funding

  • 19 research grants from peer-review agencies since 1987, 16 as principal investigator and 3 as co-investigator.
  • Career Scientist Award from Ontario Ministry of Health in external competition, successfully renewed for 10 years.
  • Total funding awarded by peer-reviewed agencies over 2 million dollars thus far.
  • Continuous funding from NSERC since 1992, recently renewed through 2005.
  • Funding from Ontario Mental Health Foundation and Schizophrenia Society of Ontario since 1994, recently renewed through 2003.
  • Funding from the Stanley Foundation/NAMI through 2002.
  • Career Award from OMHF to my post-doctoral student Sarah Garside, M.D., Ph.D., starting July 2001.
  • Dr. Mazurek currently supervises five graduate students, with a 6th scheduled to start in September (2001). Each of these students has won funding from an external granting agency, three from NSERC, two from OGS and one from CIHR/PMAC

Honours and Awards

  • Elected to membership in American Neurological Association, October 2000.
  • New Investigator Career Award to post-doctoral student, Sarah Garside, from OMHF.
  • Appointment to Research Grants Committee for the Ontario Mental Health Foundation and the Schizophrenia Society of Ontario.
  • Students from Dr. Mazurek's lab have won the Research Day prize from the Department of Psychiatry four times in the past 5 years; students working under his supervision have won the Lillian Rose Stegne Award from the Department of Psychiatry in three of the past five years.

Current Research

  • Neural signaling in the straitum and its relevance for behaviour, funded by NSERC.
  • The neural biological mechanisms of action of antipsychotic drugs, funded by OMHF and SSO.
  • The treatment of first-onset psychosis in neuroleptic naive patients, funded by Stanley Foundation/NAMI.
  • Prospective study of long-term outcome in patients presenting with first-onset psychosis, funded by OMHF.
  • Neuroimmunology of acute drug toxicities.
  • Catatonia and its relationship to the psychomotor retardation of depression.
  • Prospective study of late-onset psychotic illness.

Selected Publications

Books

  1. Mazurek MF, Rosebush PI, Garside S, Levinson AL: From the Gene to the Psychiatry Clinic: The Neuropsychiatry of Inherited Metabolic Illness. Marcel Decker Publisher, NY; in preparation.

Peer-Reviewed Contributions to Books

  1. Beal MF, Uhl G, Mazurek MF, Kowall N, Martin JB: Somatostatin: alterations in the central nervous system in neurological diseases. Neuropeptides in Neurologic and Psychiatric Disease, Martin JB, Barchas JD, eds. Raven Press, NY (1986); 215-257

  2. Martin JB, Beal MF, Mazurek MF, Kowall NW, Growdon JH: Some observations on the significance of neurotransmitter changes in Alzheimer's disease. Aging and the Brain, Terry R, ed., Raven Press, NY (1988)

  3. Mazurek MF, Beal MF, Ellison DW, Knowlton SF, Swartz KJ, Martin JB: Cholecystokinin immunoreactivity in Huntington's disease: widespread increases in postmortem cerebral cortex. The Neuropeptide Cholecystokinin, Hughes J, Dockray GJ, Woodruff GN, Eds., Ellis Horwood, UK (1989); 28-32

Peer-Reviewed Journal Articles

  1. Mazurek MF, Norris JW: Inappropriate antidiuresis and the deteriorating stroke.Trans Am Neurol Assoc, (1981); 346-349
  2. Kasting NW, Mazurek MF, Martin JB: Endotoxin increases vasopressin release in- dependently of known physiological stimuli. Am J Physiology, (1985); 248:E420-424
  3. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martin JB: Somatostatin receptors are reduced in Alzheimer's disease cerebral cortex. Science, (1985); 229:289-291
  4. Beal MF, Mazurek MF, Black PM, Martin JB: Human cerebrospinal fluid somatostatin in neurologic disease. J Neurological Sciences, (1985); 71:91-104
  5. Beal MF, Tran VT, Mazurek MF, Chattha G, Martin JB: Somatostatin binding sites in human and monkey brain: localization and characterization. J Neurochemistry, (1986); 46:359-365
  6. Mair RG, Langlais PJ, Mazurek MF, Beal MF, Martin JB, McEntee WJ: Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's amnesia. Life Sciences, (1986), 38:2301-2306
  7. Beal MF, Growdon JH, Mazurek MF, Martin JB: CSF somatostatin-like immunoreactivity in dementia. Neurology, (1986); 36:294-297
  8. Mazurek MF, Growdon JH, Beal MF, Martin JB: CSF vasopressin concentration is reduced in Alzheimer's disease. Neurology, (1986); 36:1133-1137
  9. Beal MF, Mazurek MF, Lorenz L, Chatta G, Ellison D, Martin JB: Examination of neuropeptide Y postmortem stability using a new radioimmunoassay. Neuroscience Letters, (1986); 64:69-74
  10. Beal MF, Benoit R, Mazurek MF, Martin JB: Somatostatin 28 (1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Research, (1986); 368:380-383
  11. Mazurek MF, Beal MF, Martin JB: Neuropeptides and Alzheimer's disease: clinical implications. Neurologic Clinics, (1986); 4:753-768
  12. Randle JCR, Mazurek MF, Kneifel D, Dufresne J, Renaud LP: Alpha-1 adrenergic receptor activation releases vasopressin and oxytocin from perfused rat hypothalamic explants. Neuroscience Letters, (1986); 65:219-223
  13. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB: Duplication of the neurochemical characteristics of Huntington's disease with quinolinic acid. Nature, (1986); 321:168-171
  14. Beal MF, Mazurek MF, Chattha G, Lorenz L, Bird ED, Martin JB: Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Annals of Neurology, (1986); 20:282-288
  15. Beal MF, Mazurek MF, Svendsen CN, Bird ED, Martin JB: Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease. Annals of Neurology, (1986); 20:489-495
  16. Mazurek MF, Beal MF, Bird ED, Martin JB: Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations. Annals of Neurology, (1986); 20:665-670
  17. Ellison D, Beal MF, Mazurek, MF Martin JB: A postmortem study of free amino acids in Alzheimer's disease. Annals of Neurology, (1986); 20:616-621
  18. Beal MF, Mazurek MF, Martin JB: Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Research, (1986); 397:386-388
  19. Mazurek MF, Beal MF, Martin JB: Oxytocin in Alzheimer's disease: postmortem brain levels. Neurology, (1987); 37:1001-1003
  20. Beal MF, Mazurek MF: Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology, (1987); 37:1205-1209
  21. Beal MF, Kowall NW, Mazurek MF: Neuropeptides in Alzheimer's disease. J. Neural Transm, (1987) [Suppl]; 24:163-174
  22. Ellison DW, Beal MF, Mazurek MF, Malloy JR, Martin JB: Amino acid neuro-transmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain, (1987); 110:1657-1673
  23. Beal MF, Mazurek MF, McKee MA: The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum. Neuroscience Letters, (1987); 79:201-206
  24. Beal MF, Mazurek MF, Martin JB: A comparison of somatostatin and neuropeptide Y distribution in monkey brain. Brain Research, (1987); 405:213-219
  25. Atack JR, Beal MF, May C, Kaye J, Mazurek MF, Kaye AD, Rapoport SI: Cerebrospinal fluid somatostatin and neuropeptide Y: concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs. Archives of Neurology, (1988); 45:269-274
  26. Beal MF, Ellison DW, Mazurek MF, Swartz KJ, Malloy JR, Bird ED, Martin JB: A detailed examination of substance P in pathologically graded cases of Huntington's disease. J. Neurological Sciences, (1988); 84:51-61
  27. Beal MF, Mazurek MF, Ellison DW, Swartz KW, Malloy JR, Bird ED, Martin JB: Somatostatin and Neuropeptide Y Concentrations in Pathologically Graded Cases of Huntington's Disease. Annals of Neurology, (1988); 23:562-569
  28. Antoni FA, Kovacs KJ, Dohanits J, Makara GB, Holmes MC, Mazurek MF: Hypophysiotrophic function of vasopressin and oxytocin. Brain Research Bulletin, (1988); 20:729-736
  29. Beal MF, Clevens R, Mazurek MF: Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer changes. Synapse, (1988); 2:463-467
  30. Beal MF, McGarvey U, Clevens R, Swartz KJ, Mazurek MF, Gabriel S: Galanin immunoreactivity is normal in Alzheimer's disease and Parkinson's disease with dementia postmortem brain. J Neurochemistry, (1988); 51:1935-1941
  31. Beal MF, Mazurek MF, Ellison DW, Kowall NW, Solomon PR, Pendlebury WW: Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits. Neuroscience, (1989); 29:339-346
  32. Brown GM, Mazurek MF, Allen D, Szechtman B, Cleghorn JM: Dose-response profiles of plasma growth hormone and vasopressin following clonidine challenge in man. Psychiatry Research, (1990); 31:311-320
  33. Rosebush PI, Hildebrand A, Furlong B, Mazurek MF: Catatonic syndrome on a general psychiatry ward: frequency, clinical presentation and response to lorazepam. J Clin Psychiatry, (1990); 51:357-362
  34. Mazurek MF, Rosebush PI: Tardive dyskinesia and the law. (editorial) Can J Psychiatry (1990); 35:573-574
  35. Rosebush, PI, Mazurek MF: Bromocriptine in the treatment of neuroleptic malignant syndrome. J Clin Psychiatry, (1991); 52:41-42
  36. Mazurek MF, Beal MF: Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology, (1991); 41:716-719
  37. Rosebush, PI, Mazurek MF: Low serum iron in neuroleptic malignant syndrome. (letter) Am J Psychiatry, (1991); 148:148-149
  38. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW. Neurochemical characterization of excitotoxin lesions in cerebral cortex. J Neuroscience, (1991); 11:147-158
  39. Furtado JCS, Mazurek MF: MPTP-induced neurotoxicity and the quest for a preventive therapy for Parkinson's disease. Can J Neurol Sci, (1991); 18:77-82
  40. Rosebush, PI, Mazurek MF: A consideration of the mechanisms by which lorazepam might treat catatonia. J. Clin. Psychiatry (1991); 52:187-188
  41. Rosebush PI, Mazurek MF: Serum iron in neuroleptic malignant syndrome. Lancet (1991); 338:149-151; 820-821
  42. Rosebush PI, Stewart T, Mazurek MF: treatment of neuroleptic malignant syndrome: are dantrolene and bromocriptine useful adjuncts to supportive care? British J Psychiatry, (1991); 159:709-712
  43. Rosebush PI, Mazurek MF: Iron in neuroleptic malignant syndrome. Lancet, (1991); 338:820-821
  44. Mazurek MF: Brain endocrinology. (review) Neurology, (1992); 42:1437-1438
  45. Storey E, Kowall NW, Finn SF, Mazurek MF, Beal MF. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex. Annals of Neurology (1992);32:526-534
  46. Rosebush PI, Hildebrand AM, Mazurek MF: The treatment of catatonia: benzodiazepines or ECT? Am J Psychiatry, (1992); 149:1279
  47. Rosebush PI, Mazurek MF: Do benzodiazepines modify the incidence of neuroleptic-induced dystonia? Am J Psychiatry, (1993); 150:528
  48. Kish SJ, Robitalle Y, El-Awar M, Schut L, DiStefano L, Ball MJ, Mazurek MF: Reduced cerebral cortical but elevated striatal concentration of somatostatin-like immunoreactivity in dominantly-inherited olivopontocerebellar atrophy. J Neurology Neurosurgery and Psychiatry, (1993); 56:1013-1015
  49. Mazurek MF: Huntington's Disease: a diagnostic breakthrough. (editorial). Geriatrics (1993); 9:1
  50. Gaind G, Rosebush PI, Mazurek MF: Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. J Clin Psychiatry, (1994); 55:20-23
  51. Rosebush PI, MacQueen GM, Mazurek MF: Late-onset Tay-Sachs Disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry, (1995); 56:347-353
  52. Rosebush PI, Mazurek MF: Complicating factors in the analysis of acute drug-induced akathisia. Arch Gen Psychiatry, (1995); 52: 878-880
  53. Furtado JCS, Mazurek MF: Behavioural characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease. Experimental Neurology, (1996); 138:158-168
  54. Mazurek MF, Rosebush PI: Circadian pattern of acute neuroleptic-induced dystonic reactions. Am J Psychiatry, (1996); 153:708-710
  55. Rosebush PI, Mazurek MF: Catatonia after benzodiazepine withdrawal. J Clin Psychopharmacology, (1996); 16:315-319
  56. Garside S, Furtado JCS, Mazurek MF: Dopamine-glutamate interactions in the striatum: behaviorally relevant modification of excitotoxicity by dopamine-receptor-mediated mechanisms. Neuroscience, (1996); 75: 1065-1074
  57. Garside S, Woulfe J, Mazurek MF: The ontogeny of NADPH-diaphorase neurons in vivo and in serum-free cultures of primary striatal neurons. Neuroscience, (1997); 78:613-624.
  58. Mazurek MF, Garside S, Beal MF: Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Annals of Neurology, (1997); 41:540-547
  59. Rosebush PI, Kennedy K, Dalton B, Mazurek MF: Protracted akathisia after risperidone withdrawal. Am J Psychiatry, (1997); 154:437-438
  60. Garside S, Mazurek MF: The role of glutamate receptor subtypes in the differential release of somatostatin, neuropeptide Y and substance P from serum-free cultures of striatal neurons. Synapse (1998); 27:161-167
  61. Mazurek MF, Savedia SM, Bobba RS, Garside S, Rosebush PI: Persistent loss of tyrosine hydroxylase immunoreactivity in substantia nigra following neuroleptic withdrawal. J Neurol Neurosurg Psychiatry, (1998); 64:799-801
  62. MacQueen GM, Rosebush PI, Mazurek MF: Neuropsychiatric aspects of the adult variant of Tay-Sachs Disease. J Neuropsychiatry & Clin Neurosciences, (1998); 10:10-19
  63. Levinson AL, Garside S, Rosebush PI, Mazurek MF: Haloperidol induces persistent downregulation of tyrosine hydroxylase immunoreactivity in substantia nigra, but not ventral tegmental area, in the rat. Neuroscience, (1998) ; 84:201-211
  64. Rosebush PI, Margetts P, Mazurek MF: Serotonin syndrome secondary to clomipramine monotherapy. J Clin Psychopharmacol; (1999); 19:285-287
  65. Rosebush PI, MacQueen GM, Mazurek MF: Catatonia following gabapentin withdrawal. J Clin Psychopharmacol; (1999); 19:188-189
  66. Rosebush PI, Mazurek MF: The neurological side effects of risperidone. Essential Psychopharmacol (1999);3:43-63
  67. Rosebush PI, Mazurek MF: Catatonia: re-awakening to a forgotten disorder. Movement Disorders (1999); 14:395-397
  68. Rosebush PI, Mazurek MF: Neurological side effects in neuroleptic-naïve patients treated with risperidone or haloperidol. Neurology, (1999); 52:782-785
  69. Garside S, Rosebush PI, Levinson AJ, Mazurek MF: Late-onset adrenal-leukodystrophy associated with long-standing psychiatric symptoms. J Clin Psychiatry. (1999); 60:460-468
  70. Rosebush PI, Garside S, Levinson A, Mazurek MF: The neuropsychiatry of adult-onset adrenoleukodystrophy: J Neuropsychiatry & Clin Neurosciences, 1999; 11:315-327
  71. Garside S, Rosebush PI, Levinson AL, Mazurek MF: MRI abnormalities and psychiatric illness. Am J Psychiatry (1999); (2000); 157: 306-307
  72. Mazurek MF, Rosebush PI: Foundations for the classification of catatonia. Movement Disorders, (2000); 15:180-181
  73. Mazurek MF, Rosebush PI: The search for an optimal dosage of risperidone. Neurology, (2000); 54:1543-1544
  74. Mazurek MF, Rosebush PI. Risperidone-induced extrapyramidal syndromes. Neurology (2000); (in press)
  75. Furtado JCS, Mazurek MF: A role for the lateral striatum in the mediation of visuospatial cognition. Neuroscience; in revision
  76. Rosebush PI, Mazurek MF: The risk of neuroleptic malignant syndrome in patients with catatonia. Movement Disorders (2000); in revision.
  77. Garside S, Mazurek MF: The actions and interactions of dopamine and glutamate receptor agonists in the control of somatostatin, neuropeptide Y and substance P release from striatal neurons in serum-free primary cultures. Neuroscience; in revision.
  78. Garside S, Rosebush PI, Levinson A, Mazurek MF: Late-onset metachromatic leukodystrophy presenting in schizophrenia: case report and review of the literature. J Clin Psychiatry (submitted)
  79. Rosebush PI, Mazurek MF. Long-term follow-up and improvement of a patient with GM2 gangliosidosis treated with high dose benzodiazepine. Neurology (submitted).
  80. Mazurek MF, Hollenberg R, Levinson AL, Garside S, Rosebush PI: Neuroleptic-induced downregulation of midbrain dopaminergic neurons is attenuated by benztropine or lorazepam. J Clin Psychopharmacol (2000) submitted.
  81. Chong D, Mazurek MF: The effects of striatal lesions on Morris Water Maze behaviour in the rat: impaired task acquisition but preserved visual-spatial memory. (submitted)

Published Abstracts (Peer-Reviewed)

  1. Mazurek MF, Norris JW: SIADH and the deteriorating stroke. Annals of Neurology, (1981); 10:104
  2. Mazurek MF: Vasopressin and inappropriate antidiuresis in stroke and sub-arachnoid hemorrhage. Can J Neurol Sci, (1982); 9:297
  3. Mazurek MF, Kasting NW, Martin JB: Neuroendocrine and physiological responses to endotoxin in the rat. Neuroscience Abst, (1983); 9:417
  4. Mazurek MF, Growdon JH, Beal MF, Martin JB: CSF vasopressin levels are reduced in Alzheimer's disease. Neurology, (1984); 34(Suppl. 1):280
  5. Beal MF, Growdon JH, Mazurek MF, Martin JB: CSF somatostatin in dementia. Neurology, (1984); 34 (Suppl. 1):120
  6. Mazurek MF, Kasting NW, Martin JB: Endotoxin-induced prolactin and beta-endorphin release in the rat: effects of naloxone and indomethacin. Abst. 7th Int.Congress Endocrinology, (1984); 951
  7. Mazurek MF, Beal MF, Martin JB: Cortical and subcortical distribution of arginine vasopressin in human brain. Endocrinology, (1985); 116 (Suppl. 1):217
  8. Mazurek MF, Beal MF, Martin JB: Vasopressin in postmortem Alzheimer brain. Annals of Neurology, (1985); 19:143-144
  9. Beal MF, Mazurek MF, Chattha G, Martin JB: Somatostatin-like immuno- reactivity in Alzheimer's disease. Annals of Neurology, (1985); 18:144
  10. Mazurek MF, Randle JC, Kneifel D, Renaud LP: Alpha-1 adrenoreceptor-mediated release of arginine vasopressin (AVP) and oxytocin (OXY) from perfused rat hypothalamus-neurohypophysial explants. Neuroscience Abst, (1985) 11:1057
  11. Ellison DW, Beal MF, Mazurek MF, Martin JB: An evaluation of extraction techniques for neuropeptides in human brain. Neuroscience Abst, (1985); 11:567
  12. Beal MF, Mazurek MF, Chattha G, Bird ED, Martin JB: Neuropeptide Y immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neuroscience Abst, (1985); 11:1119
  13. Antoni FA, Mazurek MF, Holmes MC: Is oxytocin a hypophysiotropic hormone? 5th Joint Meeting of British Endocrine Society, (1986)
  14. Antoni FA, Mazurek MF, Holmes MC: The median eminence: A site where neuropeptides are released by "Axons in Passage". 4th Brain Research Assoc Meeting, (1986)
  15. Mazurek MF, Beal MF, Martin JB: Oxytocin in postmortem Alzheimer brain. Neurology, (1986); 36 (Suppl. 1):271
  16. Beal MF, Mazurek MF, Martin JB: Substance P-like immunoreactivity is reduced in Alzheimer cerebral cortex. Neurology, (1986); 36 (Suppl. 1):273
  17. Mazurek MF, Beal MF, Malloy JR, Martin JB: Vasoactive intestinal peptide immunoreactivity in Alzheimer cerebral cortex. Annals of Neurology, (1986); 20:126
  18. Beal MF, Ellison DW, Mazurek MF, Malloy JR, Bird ED, Martin JB: Neuropeptide Y is increased in Huntington's disease. Annals of Neurology, (1986) 20:152
  19. Black PM, Mazurek MF, Martin JB: CSF vasopressin is elevated in hydrocephalus associated with high intracranial pressure but not in normal pressure hydrocephalus. Neuroscience Abst, (1986); 12:88
  20. Mazurek MF, Morton MT, Schwartz WJ: Circadian temperature rhythm is preserved in the Brattleboro rat. Neuroscience Abst, (1986); 12:1069
  21. Beal MF, Ellison DW, Mazurek MF, Bird ED, Martin JB: A detailed examination of substance P in pathologically graded cases of Huntington's disease. Neurosci Abst, (1986); 12:565
  22. Mazurek MF, Beal MF, Malloy J, Martin JB: Cholecystokinin and somatostatin in Alzheimer's disease: comparative changes in postmortem cerebral cortex. Neurology, (1987); 37(Suppl. 1):330
  23. Beal MF, Mazurek MF, Ellison DW, Kowall NW, Pendlebury WW: Neurochemical characteristics of aluminum induced neurofibrillary degeneration in rabbits. Neurology, (1987); 37(Suppl. 1):188
  24. Mazurek MF, Vale WW, Beal MF, Martin JB: Corticotropin-releasing factor and somatostatin in Alzheimer's disease: comparative changes in postmortem cerebral cortex. Annals of Neurology, (1987); 22:122-123
  25. Mazurek MF, Beal MF, Knowlton SF, Ellison DW, Bird ED, Martin JB: Chole-cystokinin and vasoactive intestinal polypeptide in the striatum of pathologically graded cases of Huntington's disease. Neurosci. Abst, (1987); 13:214
  26. Mazurek MF, Beal MF: Neuropeptides in Alzheimer's disease: comparative changes in postmortem cerebral cortex. Proc 141st meeting of the American Psychiatric Association, (1988); NR 217
  27. Rosebush PI, Mazurek MF: Abnormalities of serum iron, calcium and magnesium in neuroleptic malignant syndrome. Proc 141st meeting of the American Psychiatric Association, (1988); NR 78
  28. Mazurek MF, Beal MF, Ellison DW, Martin JB: Somatostatin, neuropeptide Y and vasoactive intestinal polypeptide in Huntington's disease: no relationship between neuropeptide levels and degrees of tissue atrophy. Can J Neurol Sci, (1988)
  29. Mazurek MF, Knowlton SF, Beal MF: Reduced concentrations of vasopressin in the substantia nigra pars compacta in postmortem Parkinson's disease brain. Annals of Neurology, (1988); 24:148
  30. Mazurek MF, Beal MF, Swartz KJ, Knowlton SF, Patel P, Martin JB: Vasoactive intestinal peptide (VIP) and cholecystokinin (CCK) in quinolinate-lesioned rats and Huntington's disease postmortem brain. Neuroscience Abst, (1988); 14:1046
  31. Mazurek MF, Beal MF, Ellison DW, Knowlton SF, Swartz KJ, Martin JB: Cholecystokinin immunoreactivity in Huntington's disease: widespread increases in postmortem cerebral cortex. Symposium on Cholecystokinin, (1988)
  32. Mazurek MF, Beal MF: Neuropeptides in Huntington's disease cerebral cortex. 142nd Annual Meeting of the American Psychiatric Association, (1989); p.88
  33. Rosebush PI, Hilldebrand A, Mazurek MF, Furlong B: Lorazepam treatment of catatonia: a study of 7 cases. 142nd Annual Meeting of the American Psychiatric Association, (1989); NR 277
  34. Mazurek MF, Beal MF, Knowlton SF, Swartz KJ, Martin JB: Elevated concentrations of cholecystokinin and vasoactive intestinal peptide in Huntington's disease postmortem cerebral cortex. Neurology, (1989); 39(Suppl. 1):203
  35. Beal MF, Clevens RA, Chattha GK, MacGarvey UM, Mazurek MF, Gabriel SM: Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex. Neurology, (1989); 39(Suppl. 1):397
  36. Mazurek MF, Garnett ES, Upton ARM, Groves JT: Creutzfeldt-Jacob disease with PET-scan changes mimicking those seen in Huntington's disease. Can J Neurol Sci, (1989); 16:244-5
  37. Mazurek MF, Beal MF: Patterns of neuropeptide changes in Alzheimer's disease cerebral cortex. Can J Neurol Sci, (1989); 16:245
  38. Mazurek MF, Swartz KW, Garside S, Beal MF: Dose-dependent decrease of vasoactive intestinal peptide (VIP) but not cholecystokinin (CCK) following kainic acid lesions of the striatum. Neurosci Abst, (1989); 15:481
  39. Rosebush PI, Hildebrand A, Furlong B, Mazurek MF: Treatment of catatonia with lorazepam: a study of 15 cases. 143rd Annual Meeting of the American Psychiatric Association, (1990); p82
  40. Rosebush PI, Mazurek MF, Hiscox W: Coexistence of parkinsonism and acute dystonic reaction. 143rd Annual Meeting of the American Psychiatric Association, (1990); NR450 p220
  41. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW: Neurochemical characterization of excitotoxin lesions in cerebral cortex. Ann Neurol, (1990); 28:273
  42. Furtado JCS, Mazurek MF: Disappearance of behavioural hyperactivity in rats with kainic acid-induced striatal lesions. Neurosci. Abst. (1990); 16:199
  43. Garside S, Mazurek MF: Kainic acid toxicity in striatum is partially blocked by anticonvulsant medication. Neurosci. Abst. (1990); 16:199
  44. Mazurek MF, Garside S: Haloperidol attenuates quinolinate toxicity in the striatum. Neurosci. Abst. (1990); 16:198
  45. Mazurek MF, Rosebush PI: A prospective study of neuroleptic-induced dystonia: incidence and relationship to age, sex, medications and concurrent parkinsonism. Neurology, (1991); 41(Suppl 1):274
  46. Storey E, Finn SF, Mazurek MF, Beal MF: Neurochemical changes in Huntington's disease cortex and in excitotoxin-lesioned rat cortex: a comparison. Neurology, (1991); 41 (Suppl 1): 174
  47. Rosebush PI, Mazurek MF: Serum iron in neuroleptic malignant syndrome. 144th Annual meeting of the American Psychiatric Assocation, (1991); p.97
  48. Mazurek MF, Rosebush PI: Neurochemical abnormalities in Huntington's disease cerebral cortex may occur independently of striatal atrophy. Can J Neurol Sci, (1991); 18:215
  49. Rosebush PI, Mazurek MF, Hildebrand A, Gaind G: The treatment of catatonia with lorazepam: a study of 26 cases. Can J Neurol Sci, (1991); 18:234
  50. Mazurek MF, Garside S, Rosebush PI: Dopamine receptor blockade can attenuate excitotoxin-induced tissue damage in the striatum. Can J Neurol Sci, (1991); 18:215-216
  51. Furtado JCS, Mazurek MF: Evolution of spontaneous nocturnal activity in various animal models of Huntington's disease. 3rd IBRO World Congress of Neuroscience, (1991) p. 101
  52. Garside S, Furtado JCS, Mazurek MF: Effects of chronic striatal lesions on cortical neuropeptides. Neurosci Abst, (1991); 17:1450
  53. Furtado JCS, Mazurek MF: Behavioural and anatomical analysis of rats with quinolinic acid-induced striatal lesions. Neurosci Abst, (1991); 17:1221
  54. Rosebush PI, Hildebrand AM, Gaind GS, Mazurek MF: An open trial of alprazolam in the treatment of 20 elderly depressed medically compromised inpatients. 5th Annual Meeting of American Association of Geriatric Psychiatry, (1992)
  55. Mazurek MF, Rosebush PI: Drug-induced dystonia in patients taking neuroleptic medication for the first time. Movement Disorders, (1992); 7 (suppl. 1):54
  56. Rosebush PI, Mazurek MF: The treatment of catatonic syndrome with lorazepam. Movement Disorders, (1992); 7 (suppl. 1):166
  57. Mazurek MF, Kish SJ: Neuropeptide abnormalities in cerebral cortex in olivopontocerebellar atrophy postmortem brain. Annals of Neurology, (1992); 32:271-272
  58. Rosebush PI, Mazurek MF: A prospective study of multiple acute dystonic reactions in patients taking neuroleptic medications for the first time. Movement Disorders, (1992); 7:12
  59. Mazurek MF, Rosebush PI: A prospective study of dyskinetic movements in psychiatric patients with no prior exposure to neuroleptic medication. Movement Disorders, (1992); 7:12
  60. Furtado CJS, Mazurek MF: A role for the lateral striatum in the mediation of visuospatial cognition. Neuroscience Abst, (1992); 18:1422
  61. Garside S, Mazurek MF: Comparative effects of D1 and D2 dopamine agonists on somatostatin and neuropeptide Y release in cultured striatal neurons. Neurosci Abst, (1992); 18:851
  62. Mazurek MF, Furtado CJS: A morphometric examination of extrastriatal nuclei in rats with quinolinate-induced lesions of the striatum. Neurosci Abst, (1992); 18:168
  63. Rosebush PI, Hildebrand A, Mazurek MF: Neuroleptic induced akathisia in the elderly. 146th Annual Meeting of the American Psychiatric Association, (1993)
  64. Rosebush PI, Gaind G, Hildebrand A, Mazurek MF: The catatonic syndrome: a prospective 4 year study. 146th Annual Meeting of the American Psychiatric Association, (1993)
  65. Rosebush PI, Gaind G, Hildebrand A, Mazurek MF: Special issues in catatonia. 146th Annual Meeting American Psychiatric Association, (1993)
  66. Mazurek MF, Rosebush PI: Towards a neurobiological understanding of catatonia. 146th Annual Meeting of the American Psychiatric Association, (1993)
  67. Furtado JCS, Mazurek MF: Behavioural profile of rats with quinolinate-induced lesions of the prefrontal cortex. Neurosci Abst, (1993); 10:364
  68. Kiriakopoulos ET, Garside S, Furtado JCS, Mazurek MF: Huntington's disease-like changes in striatum following chronic cortical lesions in the rat. Neurosci Abst, (1993); 19:408
  69. Garside S, Woulfe J, Mazurek MF: Ontogeny of NADPH-Diaphorase neurons in primary neuronal cultures of the striatum. Neurosci Abst, (1993); 19:132
  70. Mazurek MF, Kiriakopoulos ET: Chronic cortical lesions produce Parkinson's disease-like changes in the substantia nigra of the rat. Neurosci Abst, (1993); 19:406
  71. Rosebush PI, Mazurek MF: Serum iron and the pathophysiology of neuroleptic malignant syndrome. Proceedings of the 147th Annual Meeting of the American Psychiatric Assocation, (1994); pp 111-112
  72. Rosebush PI, Hildebrand A, Mazurek MF: The syndrome of recurring catatonia: treatment and relationship to underlying illness. Proceedings of the 147th Annual Meeting of the American Psychiatric Assocation, (1994); p. 129
  73. Mazurek MF, Rosebush PI. Catatonia: Relationship to other neuropsychiatric conditions. Proceedings of the 147th Annual Meeting of the American Psychiatric Association, (1994): p. 130
  74. Rosebush PI, Hildebrand A, Mazurek MF. Neuroleptic-induced akathisia in older patients: a prospective study. Proceedings of the 147th Annual Meeting of the American Psychiatric Association, (1994); p. 27
  75. Rosebush PI, Mazurek MF: Acute neuroleptic-induced dystonic reactions have a circadian pattern. Can J Neurol Sci, (1994); 21:S28
  76. Mazurek MF, Kiriakopoulos E, Furtado S, Garside S, Woulfe J: Delayed atrophy of basal ganglia nuclei following localized lesions of the cerebral cortex: implications for stroke. Can J Neurol Sci, (1994); 21:S49
  77. Rosebush PI, Mazurek MF: Relationship Between Primary Diagnosis and Responsiveness to Lorazepam in Patients Presenting to a Psychiatric Service with Catatonia. Annals of Neurology, (1994); 36:279-280
  78. Mazurek MF, Garnett ES, Nahmias C, Furtado S, Talalla A, Garside S, Woulfe J, Rosebush P: Positron Emission Tomography Scan Studies in a Primate Model of Striatal 24 Degeneration: Implications for the Mitochondrial Hypothesis of Huntington's disease. Annals of Neurology, (1994); 36:316
  79. Mazurek MF, Rosebush PI: Parkinson disease-like changes in substantia nigra following short-term haloperidol treatment in the rat. Proceedings of the XVth Washington International Symposium on Neurodegenerative Disease, (1995)
  80. Cebrian C, Rosebush PI, Mazurek MF: Late-onset psychosis: Treatment response and outcome. Proceedings of 148th Annual Meeting of the American Psychiatric Association, (1995); in press
  81. Rosebush PI, Mazurek MF: Catatonia following withdrawal of benzodiazepine medication. Can J Neurol Sci, (1995); 22:S21
  82. 82. Rosebush PI, Mazurek MF: Reversible neurological and psychiatric abnormalities in adult GM2 gangliosidosis: The role of neuroleptic withdrawal and benzodiazepine treatment. Can J Neurol Sci, (1995); 22:S21-22
  83. Mazurek MF, Rosebush PI: Clinical and experimental evidence of persistent parkinsonism and dopaminergic cell loss in substantia nigra following neuroleptic treatment. Can J Neurol Sci, (1995); 22:S16-17
  84. Mazurek MF, Rosebush PI: Diurnal variation in acute neuroleptic-induced dystonia. Annals of Neurology, (1995); 38:299-300
  85. Savedia SM, Bobba RS, Kiriakopoulos ET, Garside S, Rosebush PI, Mazurek MF: Degeneration of dopaminergic neurons in the substantia nigra following haloperidol treatment in the rat. Neurosci Abst, (1995)
  86. Rosebush PI, Mazurek MF: Risk of NMS in patients with catatonia. Proceedings of the 149th Annual Meeting of the American Psychiatric Association, (1996); p. 30
  87. Rosebush PI, Mazurek MF: Neurological side-effects of risperidone. Proceedings of the 149th Annual Meeting of the American Psychiatric Association, (1996); p. 38
  88. Levinson AJ, Garside S, Rosebush PI, Mazurek MF: Tardive suppression of dopamine neurons in substantia nigra (SN) but not ventral tegmental area (VTA) following neuroleptic administration. Proceedings of the 149th Annual Meeting of the American Psychiatric Association, (1996); NR p. 116
  89. Cebrian C, Rosebush PI, Franco S, Mazurek MF: Depressive symptoms in late-onset psychosis. Proceedings of the 149th Annual Meeting of the American Psychiatric Association, (1996); p. 22
  90. Mazurek MF, Beal F: The neurochemical pathology of Alzheimer's disease: neuropeptide abnormalities of postmortem cerebral cortex. Neurobiology of Aging, (1996); 17: S85
  91. Levinson AJ, Garside S, Rosebush PI, Mazurek MF: Persistent downregulation of tyrosine hydroxylase in substantia nigra but not ventral tegmental area following withdrawal from haloperidol. Neurosci Abst, (1996); 22:177
  92. Rosebush PI, Mazurek MF. Extrapyramidal side-effects of risperidone. Neurology, (1997)
  93. Rosebush PI, Mazurek MF. Catatonia: underlying diagnosis and response to lorazepam. Proceedings of the 150th Annual Meeting of the American Psychiatric Association, (1997); page 69
  94. Rosebush PI, Mazurek MF. Extrapyramidal symptom profiles in older neuroleptic-naive patients. Proceedings of the 150th Annual Meeting of the American PsychiatricAssociation, (1997); pp 17-18
  95. Rosebush PI, Mazurek MF: Relationship between catatonia and NMS. Proceedings of the American Psychiatric Association, (1997) page 174 #118C
  96. Mazurek MF, Nahmias C, Coates G, Rosebush P: Normal striatal glucose metabolism by PET in patients with confirmed Huntington's disease. Can J Neurol Sci, (1997); 24:554
  97. Rosebush P, Mazurek M, Levinson A, Garside S: The prevalance of cobalamin deficiency in acutely ill psychiatric patients. Can J Neurol Sci, (1997); 24:554-55
  98. Garside S, Mazurek MF: Dopamine-glutamate interactions in the regulation of neuropeptide release from striatal neurons in serum-free primary culture. Neurosci Abst, (1997); 23:748
  99. Mazurek MF, Garside S: The role of glutamate receptor subtypes in the differential release of somatostatin, neuropeptide Y and substance P from primary serum-free cultures of striatal neurons. Neurosci Abst, (1997); 23:188
  100. Chong DJ, Mazurek MF: The effects of striatal lesions on performance in a water maze: Evidence of involvement of the striatum in procedural learning. Neurosci Abst, (1997), 23:469
  101. Levinson AJ, Garside S, Rosebush PI, Mazurek MF: Calbindin-immunoreactive cells are not spared in neuroleptic-induced downregulation of midbrain dopamine neurons. Neurosci Abst (1997); 23:194
  102. Rosebush PI, Mazurek, MF: NMS and catatonia: comparative features. 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario. (June 1998)
  103. Rosebush PI, Mazurek MF, Garside S, Levinson AJ: Diagnostic challenges in neuropsychiatry. 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario. (June 1998)
  104. Garside S, Rosebush PI, Levinson A, Mazurek MF: Serum iron and neuroleptic-induced akathisia. Neurosci Abst, (1998); 24:501
  105. Chan, V, Garside S, Mazurek MF: Serotonin and glutamate regulation of substance P release from primary cultures of striatal neurons. Neurosci Abst, (1998); 24:1649
  106. Harrison SJ, Mazurek MF: Comparative effects of antipsychotic and antidepressant drugs on dopaminergic, noradrenergic and serotonergic cell groups in the rat. Neurosci Abst, (1998); 24: 2179
  107. Rosebush PI, Mazurek MF: Risperidone-induced dyskinesias. 152nd Annual Meeting of the American Psychiatric Association, Washington D.C. (May 1999)
  108. Rosebush PI, Mazurek MF, Garside S, Levinson AJ: Diagnostic challenges in neuropsychiatry. 152nd Annual Meeting of the American Psychiatric Association, Washington D.C. (May 1999)
  109. Mazurek MF, Kolbasnik A, Garside S, Levinson A, Rosebush PI: Can neuroleptics cause Parkinson's disease? Ann Neurol (1999); 46:487
  110. Mazurek MF, Chong DJ, Ramakrishnan K: The differential roles of striatum and hippocampus in performance of a water maze: procedural learning vs. visuospatial memory. Neurosci Abst (1999); 25:91
  111. Kolbasnik A, Garside S, Levinson AJ, Rosebush PI, Mazurek MF: Haloperidol induces Parkinson's disease-like cell loss in substantia nigra in aged rats. Neurosci Abst (1999); 25:333
  112. Chan VH, Mazurek MF: Selective dopamine receptor agonists differentially modify glutamate-induced release of substance P from striatal neurons. Neurosci Abst (1999); 25:377
  113. Krasnik CE, Rosebush PI, Mazurek MF: Mitochondrial Inhibition increases the toxic effects of antipsychotic drugs and induces apoptosis in midbrain dopamine neurons. Neurosci Abst (2001); in press.
  114. Mazurek MF, Krasnik CE, Rosebush PI, Garside S: Antipsychotic drugs activate prostate apoptosis response-4 and caspase-3 in midbrain dopamine neurons of young animals co-treated with 3-nitroproprionic acid. Neurosci Abst (2001); in press.
  115. Rosebush PI, Garside S, Levinson AJ, Schroeder J, Richards CD, Mazurek MF: The neuroimmunology of antidepressant medication: serotonin syndrome as a manifestation of the acute phase response. Neurosci Abst (2001); in press.